Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
13.72
-0.49 (-3.45%)
May 15, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Contineum Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $22.33. The average 1-year stock price forecast is 62.76% higher than the current stock price, while the lowest is $16 (+16.62%) and the highest is $28 (+104.08%).
Price Target: $22.33 (+62.76%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Contineum Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $14 → $16 | Hold | Maintains | $14 → $16 | +16.62% | May 14, 2026 |
| Baird | Baird | Buy Maintains $14 → $20 | Buy | Maintains | $14 → $20 | +45.77% | Mar 6, 2026 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $23 → $14 | Buy → Hold | Downgrades | $23 → $14 | +2.04% | Jan 8, 2026 |
| Baird | Baird | Buy Maintains $16 → $14 | Buy | Maintains | $16 → $14 | +2.04% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $25 → $22 | Buy | Maintains | $25 → $22 | +60.35% | Nov 21, 2025 |
Financial Forecast
Revenue This Year
6.12M
Revenue Next Year
2.24M
from 6.12M
Decreased by -63.33%
EPS This Year
-2.23
from -2.17
EPS Next Year
-2.22
from -2.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.5M | 11.6M | ||||||
| Avg | 6.1M | 2.2M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 88.7% | ||||||
| Avg | - | -63.3% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.03 | -1.77 | ||||||
| Avg | -2.23 | -2.22 | ||||||
| Low | -2.33 | -2.68 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.